Cargando…
131I-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes.
Mathematical models have predicted that targeted radiotherapy of neuroblastoma with metaiodobenzylguanidine (mIBG) is less likely to cure small rather than large micrometastases if 131I is the conjugated radionuclide. This study uses multicellular tumour spheroids as an in vitro model to test the hy...
Autores principales: | Gaze, M. N., Mairs, R. J., Boyack, S. M., Wheldon, T. E., Barrett, A. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1992
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1978020/ https://www.ncbi.nlm.nih.gov/pubmed/1457344 |
Ejemplares similares
-
Prediction of accumulation of 131I-labelled meta-iodobenzylguanidine in neuroblastoma cell lines by means of reverse transcription and polymerase chain reaction.
por: Mairs, R. J., et al.
Publicado: (1994) -
Modification of meta-iodobenzylguanidine uptake in neuroblastoma cells by elevated temperature.
por: Armour, A., et al.
Publicado: (1994) -
Diagnostic Use of Post-therapy (131)I-Meta-Iodobenzylguanidine Scintigraphy in Consolidation Therapy for Children with High-Risk Neuroblastoma
por: Wakabayashi, Hiroshi, et al.
Publicado: (2020) -
Biomarker response to high-specific-activity I-131 meta-iodobenzylguanidine in pheochromocytoma/paraganglioma
por: Jimenez, Camilo, et al.
Publicado: (2022) -
A phase I clinical trial for [(131)I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma
por: Wakabayashi, Hiroshi, et al.
Publicado: (2019)